Company Profile
bioAffinity Technologies, Inc. Stock Price, News & Analysis
Company overview
Business overview
bioAffinity Technologies is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, bioAffinity Technologies is followed within the biotech universe for its exposure to catalyst-driven execution.
Business Model Characteristics
bioAffinity Technologies follows a catalyst-driven model where the market watches how the company turns development work into repeatable value creation.
Position Within the Biotechnology Landscape
Compared with more mature healthcare peers, bioAffinity Technologies sits closer to the development side of the biotechnology landscape, where timing around data and approvals matters most.
Why the stock is moving
BIAF is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
bioAffinity’s catalysts are lung-cancer screening adoption and any update that clarifies whether the diagnostics platform can scale. The company still needs a stronger commercial runway.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
bioAffinity Technologies Reports First Quarter 2026 Results and Expanding Adoption and Clinical Usage of CyPath® Lung
Source: bioAffinity Technologies, Inc.
- 02
- 03
- 04
bioAffinity Technologies Announces Initiation of Large-Scale Longitudinal Clinical Study for Its Noninvasive CyPath® Lung Cancer Diagnostic
Source: bioAffinity Technologies, Inc.
- 05
bioAffinity Technologies Announces Record 2025 Revenue and Unit Sales for Flagship Lung Cancer Diagnostic CyPath® Lung
Source: bioAffinity Technologies, Inc.
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.